GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The company has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
Follow-Up Questions
¿Quién es el CEO de Globeimmune Inc?
Dr. Timothy Rodell es el President de Globeimmune Inc, se unió a la empresa desde 2003.
¿Qué tal es el rendimiento del precio de la acción GBIM?
El precio actual de GBIM es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Globeimmune Inc?
Globeimmune Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Globeimmune Inc?
La capitalización bursátil actual de Globeimmune Inc es $0
